Eli Lilly & Co. vs. Ultragenyx Pharmaceutical Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| LLY | RARE | |
|---|---|---|
| Market Cap | $1.05 trillion | $1.43 billion |
| Revenue (TTM) | $79.67 billion | $717.21 million |
| Net Income (TTM) | $26.71 billion | $-585,969,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | RARE | |
|---|---|---|
| P/E Ratio | 39.77 | — |
| Price / Book | 31.14 | -4.91 |
| Price / Sales | 13.24 | 1.99 |
RARE leads on 2 of 2 valuation factors.
Profitability
| LLY | RARE | |
|---|---|---|
| Net Margin | 33.53% | -81.70% |
| Return on Equity | 78.84% | 201.36% |
LLY and RARE split the profitability factors evenly.
Dividend
| LLY | RARE | |
|---|---|---|
| Dividend Yield | 0.58% | — |
| Payout Ratio | 23.23 | — |
LLY and RARE split the dividend factors evenly.
Risk & Sentiment
| LLY | RARE | |
|---|---|---|
| Short Interest | 1.29% | 5.60% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RARE overview, RARE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.